REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 36 filers reported holding REXAHN PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $21,000 | +250.0% | 40,400 | 0.0% | 0.00% | – |
| Q4 2016 | $6,000 | -33.3% | 40,400 | 0.0% | 0.00% | – |
| Q3 2016 | $9,000 | -10.0% | 40,400 | 0.0% | 0.00% | – |
| Q2 2016 | $10,000 | -28.6% | 40,400 | 0.0% | 0.00% | – |
| Q1 2016 | $14,000 | -6.7% | 40,400 | 0.0% | 0.00% | – |
| Q4 2015 | $15,000 | -28.6% | 40,400 | 0.0% | 0.00% | – |
| Q3 2015 | $21,000 | -12.5% | 40,400 | 0.0% | 0.00% | – |
| Q2 2015 | $24,000 | -20.0% | 40,400 | 0.0% | 0.00% | – |
| Q1 2015 | $30,000 | +30.4% | 40,400 | +25.5% | 0.00% | – |
| Q4 2014 | $23,000 | -20.7% | 32,200 | -10.6% | 0.00% | – |
| Q3 2014 | $29,000 | -9.4% | 36,000 | 0.0% | 0.00% | – |
| Q2 2014 | $32,000 | -17.9% | 36,000 | 0.0% | 0.00% | – |
| Q1 2014 | $39,000 | +34.5% | 36,000 | -50.0% | 0.00% | – |
| Q4 2013 | $29,000 | +81.2% | 72,000 | +100.0% | 0.00% | – |
| Q3 2013 | $16,000 | 0.0% | 36,000 | 0.0% | 0.00% | – |
| Q2 2013 | $16,000 | – | 36,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Anson Funds Management LP | 18,340,000 | $3,852,000 | 0.41% |
| SABBY MANAGEMENT, LLC | 9,464,849 | $1,988,000 | 0.07% |
| Northeast Financial Consultants Inc | 150,000 | $31,000 | 0.01% |
| HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 200,000 | $42,000 | 0.01% |
| TWO SIGMA SECURITIES, LLC | 185,239 | $39,000 | 0.01% |
| Benin Management CORP | 93,000 | $20,000 | 0.01% |
| CONDOR CAPITAL MANAGEMENT | 145,000 | $30,000 | 0.01% |
| NIXON PEABODY TRUST CO | 10,000 | $2,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 47,677 | $10,000 | 0.00% |
| Renaissance Technologies | 3,201,993 | $672,000 | 0.00% |